Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Ovarian

Sub-indication: Platinum resistant ovarian cancer

Line of Therapy: 2nd or 3rd line

Drug/Device Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: NovoCure

Learn more at ClinicalTrials.gov

Email for more information: GYN-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.